Completed PHASE2 INTERVENTIONAL 2-arm NCT00003992

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer

Sponsor: National Cancer Institute (NCI)

Interventions cyclophosphamide doxorubicin hydrochloride paclitaxel tamoxifen citrate trastuzumab

Updated 7 times since 2017 Last updated: May 31, 2013 Started: Aug 31, 1999 Primary completion: Jan 31, 2007 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003992, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Cedar Rapids, United States , Chicago, United States , Cleveland, United States , Decatur, United States , Denver, United States and 27 more locations